rs33917957

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The NM_000245.4(MET):​c.1124A>G​(p.Asn375Ser) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.022 in 1,594,672 control chromosomes in the GnomAD database, including 630 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. N375K) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.019 ( 48 hom., cov: 33)
Exomes 𝑓: 0.022 ( 582 hom. )

Consequence

MET
NM_000245.4 missense

Scores

3
14

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:20O:1

Conservation

PhyloP100: 2.92

Publications

104 publications found
Variant links:
Genes affected
MET (HGNC:7029): (MET proto-oncogene, receptor tyrosine kinase) This gene encodes a member of the receptor tyrosine kinase family of proteins and the product of the proto-oncogene MET. The encoded preproprotein is proteolytically processed to generate alpha and beta subunits that are linked via disulfide bonds to form the mature receptor. Further processing of the beta subunit results in the formation of the M10 peptide, which has been shown to reduce lung fibrosis. Binding of its ligand, hepatocyte growth factor, induces dimerization and activation of the receptor, which plays a role in cellular survival, embryogenesis, and cellular migration and invasion. Mutations in this gene are associated with papillary renal cell carcinoma, hepatocellular carcinoma, and various head and neck cancers. Amplification and overexpression of this gene are also associated with multiple human cancers. [provided by RefSeq, May 2016]
COMETT (HGNC:51196): (cytosolic oncogenic antisense to MET transcript) This gene encodes a natural antisense transcript highly expressed in papillary thyroid carcinomas harboring BRAF V600E mutation or RET gene rearrangements. This lncRNA induces the downstream MAPK pathway and is part of a co-expression network including different oncogenes belonging to the MAPK and PI3H/AKT pathways. In thyroid carcinomas, this gene has oncogenic properties associated with increased proliferation and drug resistance. [provided by RefSeq, Jan 2020]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.0023828745).
BP6
Variant 7-116700208-A-G is Benign according to our data. Variant chr7-116700208-A-G is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 41611.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (SAS) allele frequency at 95% confidence interval = 0.0658 is higher than 0.05.

Variant Effect in Transcripts

ACMG analysis was done for transcript: NM_000245.4. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Sel.
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
MET
NM_000245.4
MANE Select
c.1124A>Gp.Asn375Ser
missense
Exon 2 of 21NP_000236.2
MET
NM_001127500.3
c.1124A>Gp.Asn375Ser
missense
Exon 2 of 21NP_001120972.1P08581-2
MET
NM_001324401.3
c.1124A>Gp.Asn375Ser
missense
Exon 2 of 12NP_001311330.1E6Y365

Ensembl Transcripts

Sel.
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
MET
ENST00000397752.8
TSL:1 MANE Select
c.1124A>Gp.Asn375Ser
missense
Exon 2 of 21ENSP00000380860.3P08581-1
MET
ENST00000318493.11
TSL:1
c.1124A>Gp.Asn375Ser
missense
Exon 2 of 21ENSP00000317272.6P08581-2
MET
ENST00000436117.3
TSL:1
n.1124A>G
non_coding_transcript_exon
Exon 2 of 20ENSP00000410980.2P08581-3

Frequencies

GnomAD3 genomes
AF:
0.0194
AC:
2953
AN:
152194
Hom.:
49
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00702
Gnomad AMI
AF:
0.0263
Gnomad AMR
AF:
0.00871
Gnomad ASJ
AF:
0.00403
Gnomad EAS
AF:
0.0624
Gnomad SAS
AF:
0.0724
Gnomad FIN
AF:
0.0446
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0192
Gnomad OTH
AF:
0.0167
GnomAD2 exomes
AF:
0.0270
AC:
6190
AN:
228932
AF XY:
0.0294
show subpopulations
Gnomad AFR exome
AF:
0.00646
Gnomad AMR exome
AF:
0.00613
Gnomad ASJ exome
AF:
0.00315
Gnomad EAS exome
AF:
0.0668
Gnomad FIN exome
AF:
0.0409
Gnomad NFE exome
AF:
0.0179
Gnomad OTH exome
AF:
0.0230
GnomAD4 exome
AF:
0.0223
AC:
32104
AN:
1442360
Hom.:
582
Cov.:
32
AF XY:
0.0237
AC XY:
16953
AN XY:
716604
show subpopulations
African (AFR)
AF:
0.00510
AC:
165
AN:
32356
American (AMR)
AF:
0.00641
AC:
256
AN:
39952
Ashkenazi Jewish (ASJ)
AF:
0.00329
AC:
82
AN:
24914
East Asian (EAS)
AF:
0.0508
AC:
2013
AN:
39606
South Asian (SAS)
AF:
0.0693
AC:
5648
AN:
81504
European-Finnish (FIN)
AF:
0.0402
AC:
2127
AN:
52854
Middle Eastern (MID)
AF:
0.0101
AC:
57
AN:
5638
European-Non Finnish (NFE)
AF:
0.0185
AC:
20426
AN:
1106002
Other (OTH)
AF:
0.0223
AC:
1330
AN:
59534
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.491
Heterozygous variant carriers
0
1770
3540
5311
7081
8851
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
824
1648
2472
3296
4120
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0194
AC:
2949
AN:
152312
Hom.:
48
Cov.:
33
AF XY:
0.0212
AC XY:
1577
AN XY:
74472
show subpopulations
African (AFR)
AF:
0.00697
AC:
290
AN:
41580
American (AMR)
AF:
0.00870
AC:
133
AN:
15290
Ashkenazi Jewish (ASJ)
AF:
0.00403
AC:
14
AN:
3472
East Asian (EAS)
AF:
0.0621
AC:
322
AN:
5184
South Asian (SAS)
AF:
0.0721
AC:
348
AN:
4828
European-Finnish (FIN)
AF:
0.0446
AC:
474
AN:
10616
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.0192
AC:
1308
AN:
68022
Other (OTH)
AF:
0.0170
AC:
36
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
142
284
427
569
711
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
44
88
132
176
220
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0188
Hom.:
142
Bravo
AF:
0.0145
TwinsUK
AF:
0.0165
AC:
61
ALSPAC
AF:
0.0179
AC:
69
ESP6500AA
AF:
0.00675
AC:
26
ESP6500EA
AF:
0.0182
AC:
151
ExAC
AF:
0.0278
AC:
3356
Asia WGS
AF:
0.0700
AC:
244
AN:
3478

ClinVar

ClinVar submissions
Significance:Benign/Likely benign
Revision:criteria provided, multiple submitters, no conflicts
View on ClinVar
Pathogenic
VUS
Benign
Condition
-
-
7
not specified (8)
-
-
6
not provided (6)
-
-
4
Papillary renal cell carcinoma type 1 (4)
-
-
2
Hereditary cancer-predisposing syndrome (2)
-
-
1
Renal cell carcinoma (1)

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.076
BayesDel_addAF
Benign
-0.69
T
BayesDel_noAF
Benign
-0.71
CADD
Benign
19
DANN
Uncertain
0.98
DEOGEN2
Benign
0.37
T
Eigen
Benign
-0.011
Eigen_PC
Benign
0.16
FATHMM_MKL
Uncertain
0.86
D
LIST_S2
Uncertain
0.90
D
MetaRNN
Benign
0.0024
T
MetaSVM
Benign
-0.97
T
MutationAssessor
Benign
1.3
L
PhyloP100
2.9
PrimateAI
Benign
0.48
T
PROVEAN
Benign
-1.3
N
REVEL
Benign
0.15
Sift
Benign
0.096
T
Sift4G
Benign
0.21
T
Polyphen
0.043
B
Vest4
0.11
MPC
0.37
ClinPred
0.010
T
GERP RS
4.9
Varity_R
0.17
gMVP
0.41
Mutation Taster
=90/10
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs33917957; hg19: chr7-116340262; COSMIC: COSV59260365; COSMIC: COSV59260365; API